{"entity":{"id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","aka":[],"tldr":"A phase 2 trial of Tabelecleucel in brain and spinal cord tumours, sarcomas and uterine sarcoma, run by Pierre Fabre Medicament, active and no longer recruiting.","summary":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases is a phase 2 interventional study registered as NCT04554914 by Pierre Fabre Medicament, with 190 participants enrolled, started 2021-07-14 and due to reach its primary completion in 2027-06. Interventions recorded: Tabelecleucel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04554914","url":"https://clinicaltrials.gov/study/NCT04554914"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours","sarcoma","uterine-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tabelecleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04554914","phase":"2","setting":"An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)","sponsor":"Pierre Fabre Medicament","enrolled":190,"outcomes":[]},"route":"/trials/nct04554914/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/"}],"drug":[{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/"}]}}